Gene technology company Panchild announced on October 11 that it has officially signed a privatization merger agreement, corresponding to the pan-child transaction valuation of about $126 million. Under the agreement, the purchase price per common share is $0.272, representing a 42% premium over the last trading day prior to the announcement. Panson will merge with the parent company (New Genetron Holding Limited) and Panson will continue as a surviving entity and become a wholly-owned subsidiary of the parent company. The privatization transaction is expected to close in the first quarter of 2024.